Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Nuvation Bio Inc
(NY:
NUVB
)
2.570
+0.240 (+10.30%)
Official Closing Price
Updated: 7:00 PM EDT, Oct 16, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Nuvation Bio Inc
< Previous
1
2
Next >
Nuvation Bio Appoints Industry Veteran Philippe Sauvage as Chief Financial Officer
October 07, 2024
From
Nuvation Bio Inc.
Via
Business Wire
Positive Pooled Data from Nuvation Bio’s TRUST-I and TRUST-II Studies Highlight Taletrectinib’s Best-in-Class Potential for Patients with Advanced ROS1-positive NSCLC, Supporting Planned New Drug Application Submission in the Fourth Quarter of 2024
September 14, 2024
From
Nuvation Bio Inc.
Via
Business Wire
Nuvation Bio to Present at the Cantor Global Healthcare Conference
September 09, 2024
From
Nuvation Bio
Via
Business Wire
Nuvation Bio Reports Second Quarter 2024 Financial Results and Provides Business Update
August 05, 2024
From
Nuvation Bio Inc.
Via
Business Wire
Nuvation Bio Announces Updates and Upcoming Presentations for its ROS1 Inhibitor, Taletrectinib
July 23, 2024
From
Nuvation Bio Inc.
Via
Business Wire
Nuvation Bio Announces Data from Pivotal Phase 2 TRUST-I Study of its Investigational ROS1 Inhibitor, Taletrectinib, are Published in the Journal of Clinical Oncology and Reported at 2024 ASCO Annual Meeting
June 01, 2024
From
Nuvation Bio Inc.
Via
Business Wire
Nuvation Bio to Present at the Jefferies Global Healthcare Conference
May 29, 2024
From
Nuvation Bio Inc.
Via
Business Wire
Nuvation Bio Reports First Quarter 2024 Financial Results and Provides Business Update
May 14, 2024
From
Nuvation Bio Inc.
Via
Business Wire
Nuvation Bio to Present Updated Data on Taletrectinib, a ROS1 inhibitor, at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
April 24, 2024
From
Nuvation Bio Inc.
Via
Business Wire
Nuvation Bio Completes Acquisition of AnHeart Therapeutics
April 10, 2024
From
Nuvation Bio Inc.
Via
Business Wire
Nuvation Bio Announces Appointment of Colleen Sjogren as Chief Commercial Officer
March 28, 2024
From
Nuvation Bio Inc.
Via
Business Wire
Nuvation Bio to Acquire AnHeart Therapeutics in All-Stock Transaction
March 25, 2024
From
Nuvation Bio Inc.
Via
Business Wire
Nuvation Bio Doses First Patient in Phase 1/2 Study of NUV-1511 for the Treatment of Advanced Solid Tumors
March 14, 2024
From
Nuvation Bio Inc.
Via
Business Wire
Biotech’s Role in Addressing the Pancreatic Cancer Emergency
March 14, 2024
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NYSE:NVX),(NASDAQ:IBRX),(NASDAQ:ACRS),(NYSE:NUVB) EQNX::TICKER_END
Via
FinancialNewsMedia
Nuvation Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
February 29, 2024
From
Nuvation Bio Inc.
Via
Business Wire
Nuvation Bio Announces Appointment of Dr. Robert Mashal to its Board of Directors
January 08, 2024
From
Nuvation Bio Inc.
Via
Business Wire
Nuvation Bio Announces FDA Clearance of Investigational New Drug Application for NUV-1511 for the Treatment of Advanced Solid Tumors
January 08, 2024
From
Nuvation Bio Inc.
Via
Business Wire
Nuvation Bio Announces Departure of Chief Financial Officer
November 13, 2023
From
Nuvation Bio Inc.
Via
Business Wire
Nuvation Bio Reports Third Quarter 2023 Financial Results and Provides Business Update
November 02, 2023
From
Nuvation Bio Inc.
Via
Business Wire
Nuvation Bio Reports Second Quarter 2023 Financial Results and Provides Business Update
August 03, 2023
From
Nuvation Bio Inc.
Via
Business Wire
Nuvation Bio Announces Formation of Oncology-Focused Scientific Advisory Board
June 01, 2023
From
Nuvation Bio Inc.
Via
Business Wire
Nuvation Bio Reports First Quarter 2023 Financial Results and Provides Business Update
May 04, 2023
From
Nuvation Bio Inc.
Via
Business Wire
Nuvation Bio Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
March 15, 2023
From
Nuvation Bio Inc.
Via
Business Wire
Nuvation Bio Doses First Patient in Phase 1b Combination Study of NUV-868
December 19, 2022
From
Nuvation Bio Inc.
Via
Business Wire
Nuvation Bio Reports Third Quarter 2022 Financial Results and Provides Business Update
November 03, 2022
From
Nuvation Bio Inc.
Via
Business Wire
Nuvation Bio Reports Second Quarter 2022 Financial Results and Provides Business Update
August 04, 2022
From
Nuvation Bio Inc.
Via
Business Wire
Nuvation Bio Announces Discontinuation of NUV-422 Clinical Development Program
August 01, 2022
From
Nuvation Bio Inc.
Via
Business Wire
Nuvation Bio Appoints David Liu, M.D., Ph.D., as Chief Medical Officer and Kerry Wentworth as Chief Regulatory Officer
July 18, 2022
From
Nuvation Bio Inc.
Via
Business Wire
INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in Nuvation Bio Inc. with Losses of $100,000 to Contact the Firm
June 30, 2022
From
The Schall Law Firm
Via
Business Wire
INVESTIGATION NOTICE: The Schall Law Firm Encourages Investors in Nuvation Bio Inc. with Losses of $100,000 to Contact the Firm
June 29, 2022
From
The Schall Law Firm
Via
Business Wire
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit